183 related articles for article (PubMed ID: 24900864)
1. Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate.
Bhattacharya SK; Andrews K; Beveridge R; Cameron KO; Chen C; Dunn M; Fernando D; Gao H; Hepworth D; Jackson VM; Khot V; Kong J; Kosa RE; Lapham K; Loria PM; Londregan AT; McClure KF; Orr ST; Patel J; Rose C; Saenz J; Stock IA; Storer G; VanVolkenburg M; Vrieze D; Wang G; Xiao J; Zhang Y
ACS Med Chem Lett; 2014 May; 5(5):474-9. PubMed ID: 24900864
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo.
Kong J; Chuddy J; Stock IA; Loria PM; Straub SV; Vage C; Cameron KO; Bhattacharya SK; Lapham K; McClure KF; Zhang Y; Jackson VM
Br J Pharmacol; 2016 May; 173(9):1452-64. PubMed ID: 26784385
[TBL] [Abstract][Full Text] [Related]
3. Endocrine effects of the novel ghrelin receptor inverse agonist PF-5190457: Results from a placebo-controlled human laboratory alcohol co-administration study in heavy drinkers.
Lee MR; Farokhnia M; Cobbina E; Saravanakumar A; Li X; Battista JT; Farinelli LA; Akhlaghi F; Leggio L
Neuropharmacology; 2020 Jun; 170():107788. PubMed ID: 31557492
[TBL] [Abstract][Full Text] [Related]
4. Role of Molybdenum-Containing Enzymes in the Biotransformation of the Novel Ghrelin Receptor Inverse Agonist PF-5190457: A Reverse Translational Bed-to-Bench Approach.
Adusumalli S; Jamwal R; Obach RS; Ryder TF; Leggio L; Akhlaghi F
Drug Metab Dispos; 2019 Aug; 47(8):874-882. PubMed ID: 31182423
[TBL] [Abstract][Full Text] [Related]
5. Identification of potent, selective, CNS-targeted inverse agonists of the ghrelin receptor.
McClure KF; Jackson M; Cameron KO; Kung DW; Perry DA; Orr ST; Zhang Y; Kohrt J; Tu M; Gao H; Fernando D; Jones R; Erasga N; Wang G; Polivkova J; Jiao W; Swartz R; Ueno H; Bhattacharya SK; Stock IA; Varma S; Bagdasarian V; Perez S; Kelly-Sullivan D; Wang R; Kong J; Cornelius P; Michael L; Lee E; Janssen A; Steyn SJ; Lapham K; Goosen T
Bioorg Med Chem Lett; 2013 Oct; 23(19):5410-4. PubMed ID: 23953189
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of PF-05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.
Denney WS; Sonnenberg GE; Carvajal-Gonzalez S; Tuthill T; Jackson VM
Br J Clin Pharmacol; 2017 Feb; 83(2):326-338. PubMed ID: 27621150
[TBL] [Abstract][Full Text] [Related]
7. Ghrelin receptor inverse agonists: identification of an active peptide core and its interaction epitopes on the receptor.
Holst B; Lang M; Brandt E; Bach A; Howard A; Frimurer TM; Beck-Sickinger A; Schwartz TW
Mol Pharmacol; 2006 Sep; 70(3):936-46. PubMed ID: 16798937
[TBL] [Abstract][Full Text] [Related]
8. Development of Nonpeptidic Inverse Agonists of the Ghrelin Receptor (GHSR) Based on the 1,2,4-Triazole Scaffold.
Haj Salah KB; Maingot M; Blayo AL; M'Kadmi C; Damian M; Mary S; Cantel S; Neasta J; Oiry C; Péraldi-Roux S; Fernandez G; Romero GG; Perello M; Marie J; Banères JL; Fehrentz JA; Denoyelle S
J Med Chem; 2020 Oct; 63(19):10796-10815. PubMed ID: 32882134
[TBL] [Abstract][Full Text] [Related]
9. Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.
Xue CB; Wang A; Han Q; Zhang Y; Cao G; Feng H; Huang T; Zheng C; Xia M; Zhang K; Kong L; Glenn J; Anand R; Meloni D; Robinson DJ; Shao L; Storace L; Li M; Hughes RO; Devraj R; Morton PA; Rogier DJ; Covington M; Scherle P; Diamond S; Emm T; Yeleswaram S; Contel N; Vaddi K; Newton R; Hollis G; Metcalf B
ACS Med Chem Lett; 2011 Dec; 2(12):913-8. PubMed ID: 24900280
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of PF-6870961, a major hydroxy metabolite of the novel ghrelin receptor inverse agonist PF-5190457.
Sulima A; Akhlaghi F; Leggio L; Rice KC
Bioorg Med Chem; 2021 Nov; 50():116465. PubMed ID: 34662828
[TBL] [Abstract][Full Text] [Related]
11. Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.
Dow RL; Li JC; Pence MP; Gibbs EM; LaPerle JL; Litchfield J; Piotrowski DW; Munchhof MJ; Manion TB; Zavadoski WJ; Walker GS; McPherson RK; Tapley S; Sugarman E; Guzman-Perez A; DaSilva-Jardine P
ACS Med Chem Lett; 2011 May; 2(5):407-12. PubMed ID: 24900321
[TBL] [Abstract][Full Text] [Related]
12. Identification of spirocyclic piperidine-azetidine inverse agonists of the ghrelin receptor.
Kung DW; Coffey SB; Jones RM; Cabral S; Jiao W; Fichtner M; Carpino PA; Rose CR; Hank RF; Lopaze MG; Swartz R; Chen HT; Hendsch Z; Posner B; Wielis CF; Manning B; Dubins J; Stock IA; Varma S; Campbell M; DeBartola D; Kosa-Maines R; Steyn SJ; McClure KF
Bioorg Med Chem Lett; 2012 Jul; 22(13):4281-7. PubMed ID: 22677316
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of an assay for a novel ghrelin receptor inverse agonist PF-5190457 and its major hydroxy metabolite (PF-6870961) by LC-MS/MS in human plasma.
Adusumalli S; Jamwal R; Leggio L; Akhlaghi F
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Nov; 1130-1131():121820. PubMed ID: 31670107
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists.
Peukert S; Hughes R; Nunez J; He G; Yan Z; Jain R; Llamas L; Luchansky S; Carlson A; Liang G; Kunjathoor V; Pietropaolo M; Shapiro J; Castellana A; Wu X; Bose A
ACS Med Chem Lett; 2014 Oct; 5(10):1114-8. PubMed ID: 25313322
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel spiro[chromane-2,4'-piperidine] derivatives as potent and orally bioavailable G-protein-coupled receptor 119 agonists.
Koshizawa T; Morimoto T; Watanabe G; Fukuda T; Yamasaki N; Hagita S; Sawada Y; Okuda A; Shibuya K; Ohgiya T
Bioorg Med Chem Lett; 2018 Oct; 28(19):3236-3241. PubMed ID: 30145005
[TBL] [Abstract][Full Text] [Related]
16. High constitutive signaling of the ghrelin receptor--identification of a potent inverse agonist.
Holst B; Cygankiewicz A; Jensen TH; Ankersen M; Schwartz TW
Mol Endocrinol; 2003 Nov; 17(11):2201-10. PubMed ID: 12907757
[TBL] [Abstract][Full Text] [Related]
17. Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation.
Arhancet GB; Walker DP; Metz S; Fobian YM; Heasley SE; Carter JS; Springer JR; Jones DE; Hayes MJ; Shaffer AF; Jerome GM; Baratta MT; Zweifel B; Moore WM; Masferrer JL; Vazquez ML
Bioorg Med Chem Lett; 2013 Feb; 23(4):1114-9. PubMed ID: 23260349
[TBL] [Abstract][Full Text] [Related]
18. Differential functional selectivity and downstream signaling bias of ghrelin receptor antagonists and inverse agonists.
Ramirez VT; van Oeffelen WEPA; Torres-Fuentes C; Chruścicka B; Druelle C; Golubeva AV; van de Wouw M; Dinan TG; Cryan JF; Schellekens H
FASEB J; 2019 Jan; 33(1):518-531. PubMed ID: 30020830
[TBL] [Abstract][Full Text] [Related]
19. Unique interaction pattern for a functionally biased ghrelin receptor agonist.
Sivertsen B; Lang M; Frimurer TM; Holliday ND; Bach A; Els S; Engelstoft MS; Petersen PS; Madsen AN; Schwartz TW; Beck-Sickinger AG; Holst B
J Biol Chem; 2011 Jun; 286(23):20845-60. PubMed ID: 21402696
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors.
Barlaam B; Cadogan E; Campbell A; Colclough N; Dishington A; Durant S; Goldberg K; Hassall LA; Hughes GD; MacFaul PA; McGuire TM; Pass M; Patel A; Pearson S; Petersen J; Pike KG; Robb G; Stratton N; Xin G; Zhai B
ACS Med Chem Lett; 2018 Aug; 9(8):809-814. PubMed ID: 30128072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
